Ionis Pharmaceuticals Inc (IONS)

Currency in USD
26.96
-1.05(-3.75%)
Closed·
27.31+0.35(+1.30%)
·

IONS Earnings

Latest Release
Nov 09, 2026
EPS / Forecast
0.66 / -1.21
Revenue / Forecast
243M / 183.12M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2026--/-1.32--/178.88M----Free Sign Up
09/20260.660/-1.21243.00M/183.12M+154.55%+32.7%Free Sign Up
06/2026-0.690/-1.06268.00M/190.06M+34.91%+41.01%Free Sign Up
03/2026-0.560/-0.850246.00M/199.24M+34.12%+23.47%Free Sign Up
12/2025-1.41/-1.33203.00M/154.71M-6.02%+31.21%Free Sign Up
09/2025-0.800/-1.22157.00M/130.76M+34.43%+20.07%Free Sign Up
06/20250.700/-0.240452.00M/286.01M+391.67%+58.04%Free Sign Up
03/2025-0.930/-1.08132.00M/136.69M+13.89%-3.43%Free Sign Up
12/2024-0.660/-1.11227.00M/135.58M+40.54%+67.43%Free Sign Up
09/2024-0.950/-1.12134.00M/129.33M+15.18%+3.61%Free Sign Up

All numbers in USD

Ionis Pharmaceuticals Inc Earnings Call Summary for Q3/2026

  • Ionis posted Q3 EPS of $0.66 vs. expected loss of $1.21; revenue hit $243M, beating $183M estimate, yet shares plunged 28% to $28.50.
  • TRYNGOLZA launch underperformed expectations, prompting 2026 sales guidance cut to ~$50M; slower physician adoption cited as primary challenge.
  • Commercial revenue surpassed R&D revenue for first time at $136M, up 18% YoY; full-year revenue guidance maintained at $875M-$900M.
  • Company delayed sustained positive cash flow target from 2028 to 2029; ended quarter with $1.9B cash, expects year-end above $1.6B.
  • Management projects 2027 as pivotal for TRYNGOLZA expansion with improved payer coverage and prescriber adoption in severe hypertriglyceridemia market.
Last Updated: 11/09/2026, 11:10 PM
Read Full Transcript

FAQ

What Is Ionis Pharma's Earnings Per Share (TTM)?

The Ionis Pharma EPS (TTM) is -3.32.

When Is The Next Ionis Pharma Earnings Date?

Ionis Pharma will release its next earnings report on Feb 24, 2027.

What Is Ionis Pharma’s Revenue Forecasts For Upcoming Quarters?

Ionis Pharma’s revenue forecast is 178.88M.

How Did Ionis Pharma React to the Company's Latest Earnings Report?

Ionis Pharma reported a +154.55% EPS surprise and a +32.7% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by -28.49%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.